On 21 March 2018, orphan designation (EU/3/18/2004) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of diffuse large B-cell lymphoma.
In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.
The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in June 2019.
|Disease / condition||
Treatment of diffuse large B-cell lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;